|
Kohrt, Holbrook E; Thielens, Ariane; Marabelle, Aurelien et al. (2014) Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 123:678-86
|
|
Myklebust, June H; Irish, Jonathan M; Brody, Joshua et al. (2013) High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood 121:1367-76
|
|
Goldstein, Matthew J; Kohrt, Holbrook E; Houot, Roch et al. (2012) Adoptive cell therapy for lymphoma with CD4 T cells depleted of CD137-expressing regulatory T cells. Cancer Res 72:1239-47
|
|
Temmins, Caroline; Zhao, Shuchun; Lossos, Izidore S et al. (2011) HGAL protein expression persists in disorders of germinal center dissolution: potential role of HGAL in the germinal center microenvironment. Appl Immunohistochem Mol Morphol 19:266-72
|
|
Goldstein, Matthew J; Varghese, Bindu; Brody, Joshua D et al. (2011) A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors. Blood 117:118-27
|
|
Ai, Weiyun Z; Kohrt, Holbrook E K; Timmerman, John et al. (2011) Prolonged disease-free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma. Am J Hematol 86:515-8
|
|
Kohrt, Holbrook E; Houot, Roch; Goldstein, Matthew J et al. (2011) CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 117:2423-32
|
|
Younes, Sheren F; Beck, Andrew H; Ohgami, Robert S et al. (2011) The efficacy of HGAL and LMO2 in the separation of lymphomas derived from small B cells in nodal and extranodal sites, including the bone marrow. Am J Clin Pathol 135:697-708
|
|
Irish, Jonathan M; Myklebust, June H; Alizadeh, Ash A et al. (2010) B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci U S A 107:12747-54
|
|
Nicodemus, Christopher F; Wang, Lin; Lucas, Julie et al. (2010) Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy. Am J Obstet Gynecol 202:608.e1-8
|
Showing the most recent 10 out of 146 publications
